Patients with gMG face significant challenges in daily living, fatigue, and work ability, despite treatment adherence. A 2024 survey highlights poor quality of life and significant impairment in ...

To receive full access to Campaign's content including: Unrestricted access to all The Information and The Knowledge content Access to Campaign's in-depth features and coveted reports including ...

With the highest MG-ADL response rate among all drugs for gMG with phase 3 studies reported to date, Telitacicept will provide an important new treatment option gMG. Telitacicept is a novel ...

The EMA’s human medicines committee issued a positive opinion on Rystiggo (rozanolixizumab) as an add-on to standard therapy for the treatment of adult gMG patients who are anti-acetylcholine ...

Among 12 abstracts shared, the company highlighted pivotal Phase 3 study findings and real-world data underscoring the treatment’s promise and the ongoing unmet needs in gMG care. Key findings ...

Brisbane, Queensland, Australia--(Newsfile Corp. - April 25, 2025) - Graphene Manufacturing Group Limited (TSXV: GMG) ("GMG" or the "Company") provides a quarterly update with respect to the Company's ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...

The prefilled syringe will be available as a 20-to-30-second subcutaneous injection by a patient or caregiver after appropriate training or ... that participants with gMG or CIDP, or their ...